GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneThera Inc (OTCPK:GTHR) » Definitions » EBITDA Margin %

GeneThera (GeneThera) EBITDA Margin % : 0.00% (As of Sep. 2022)


View and export this data going back to 2000. Start your Free Trial

What is GeneThera EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. GeneThera's EBITDA for the three months ended in Sep. 2022 was $-0.12 Mil. GeneThera's Revenue for the three months ended in Sep. 2022 was $0.00 Mil. Therefore, GeneThera's EBITDA margin for the quarter that ended in Sep. 2022 was 0.00%.


GeneThera EBITDA Margin % Historical Data

The historical data trend for GeneThera's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneThera EBITDA Margin % Chart

GeneThera Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GeneThera Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GeneThera's EBITDA Margin %

For the Biotechnology subindustry, GeneThera's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeneThera's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneThera's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where GeneThera's EBITDA Margin % falls into.



GeneThera EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

GeneThera's EBITDA Margin % for the fiscal year that ended in Dec. 2021 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2021 )/Revenue (A: Dec. 2021 )
=-1.004/0
= %

GeneThera's EBITDA Margin % for the quarter that ended in Sep. 2022 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2022 )/Revenue (Q: Sep. 2022 )
=-0.124/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GeneThera  (OTCPK:GTHR) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


GeneThera EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of GeneThera's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneThera (GeneThera) Business Description

Traded in Other Exchanges
N/A
Address
3051 W 105th Avenue, Suite 350251, Westminster, CO, USA, 80035
GeneThera Inc is a biotechnology company using its proprietary molecular sciences and technologies dedicated to eradicating diseases such as COVID-19, Paratuberculosis, Mad Cow Disease, Chronic Wasting Disease, and E.coli and Salmonella infections. It focuses on developing novel molecular diagnostic tests, therapeutics, and vaccines through its proprietary robotic technologies. Its Molecular Robotic/AI Platform and Therapeutic strategy (MORAPAT) is designed to prevent the spread of disease from animals and at the same time, allow better control of zoonotic infectious agents. The company has also developed a molecular system for the detection of Mycobacterium Avian Paratuberculosis in the milk of infected dairy cows.
Executives
Avel Kolesnikov director 11353 COLONY CIRCLE, BROOMFIELD CO 80020
Mcnece Elmer Roy Jr 10 percent owner 632 CANTRILL DRIVE, DAVIS CA 95616
Fidra Holdings Ltd 10 percent owner CABLE BEACH COURT, ONE WEST BAY STREET, NASSAU BAHAMAS C5 00000
Steven Michael Grubner director, officer: Chief Financial Officer 728 S. PRAIRIE AVENUE, BARRINGTON IL 60010
Antonio Milici director, 10 percent owner, officer: Chief Executive Officer 3930 YOUNGFIELD, WHEAT RIDGE CO 80033
Tannya L Irizarry director, 10 percent owner, officer: Chief Administative Officer 11880 ANTLER TR, LITTLETON CO 80127

GeneThera (GeneThera) Headlines

No Headlines